Abiopharma

🔍 Aurora Daljit Singh (Executive)

Company: Neumora Therapeutics, Inc. (NMRA)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Acquired 40,890 shares of Common Stock at $0.72 per share (Direct)
  Date: 2026-08-17 | Code: M | equity_swap_involved: false | shares_owned_after: 123,660.00 | transaction_form_type: 4
• Acquired 15,355 shares of Common Stock at $0.72 per share (Direct)
  Date: 2026-08-17 | Code: M | equity_swap_involved: false | shares_owned_after: 139,015.00 | transaction_form_type: 4
• Acquired 1,424 shares of Common Stock at $0.72 per share (Direct)
  Date: 2026-08-17 | Code: M | equity_swap_involved: false | shares_owned_after: 140,439.00 | transaction_form_type: 4
• Acquired 1 shares of Common Stock at $0.72 per share (Direct)
  Date: 2026-08-17 | Code: M | equity_swap_involved: false | shares_owned_after: 140,440.00 | transaction_form_type: 4
• Sold 57,670 shares of Common Stock at $1.5055 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: false | shares_owned_after: 82,770.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 34,020 shares of Common Stock at $1.4853 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: false | shares_owned_after: 48,750.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 25,279 shares of Common Stock at $0.72 per share (Direct)
  Date: 2026-08-17 | Code: M | equity_swap_involved: false | shares_owned_after: 25,279.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 29,737 shares of Common Stock at $0.72 per share (Direct)
  Date: 2026-08-17 | Code: M | equity_swap_involved: false | shares_owned_after: 55,016.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 55,016 shares of Common Stock at $1.5047 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F3
• Acquired 34,162 shares of Common Stock at $0.72 per share (Direct)
  Date: 2026-08-18 | Code: M | equity_swap_involved: false | shares_owned_after: 82,912.00 | transaction_form_type: 4
• Sold 34,162 shares of Common Stock at $1.5847 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: false | shares_owned_after: 48,750.00 | transaction_form_type: 4 | Footnotes: F9
• Acquired 34,987 shares of Common Stock at $0.72 per share (Direct)
  Date: 2026-08-18 | Code: M | equity_swap_involved: false | shares_owned_after: 34,987.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 34,987 shares of Common Stock at $1.5859 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F10, F3
• Acquired 13,268 shares of Common Stock at $0.72 per share (Direct)
  Date: 2026-08-19 | Code: M | equity_swap_involved: false | shares_owned_after: 62,018.00 | transaction_form_type: 4
• Acquired 17,732 shares of Common Stock at $0.72 per share (Direct)
  Date: 2026-08-19 | Code: M | equity_swap_involved: false | shares_owned_after: 79,750.00 | transaction_form_type: 4
• Sold 31,000 shares of Common Stock at $1.6461 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: false | shares_owned_after: 48,750.00 | transaction_form_type: 4 | Footnotes: F11
• Acquired 30,918 shares of Common Stock at $0.72 per share (Direct)
  Date: 2026-08-19 | Code: M | equity_swap_involved: false | shares_owned_after: 30,918.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 30,918 shares of Common Stock at $1.6459 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F12, F3
• Sold 40,890 shares of Stock Option (Right to Buy) at $0.72 per share (Derivative)
  Date: 2026-08-17 | Code: M | Expires: 2031-09-20 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F5
• Sold 15,355 shares of Stock Option (Right to Buy) at $0.72 per share (Derivative)
  Date: 2026-08-17 | Code: M | Expires: 2033-01-19 | equity_swap_involved: false | shares_owned_after: 192,546.00 | transaction_form_type: 4 | Footnotes: F6
• Sold 1,424 shares of Stock Option (Right to Buy) at $0.72 per share (Derivative)
  Date: 2026-08-17 | Code: M | Expires: 2033-06-23 | equity_swap_involved: false | shares_owned_after: 70,797.00 | transaction_form_type: 4 | Footnotes: F7
• Sold 1 shares of Stock Option (Right to Buy) at $0.72 per share (Derivative)
  Date: 2026-08-17 | Code: M | Expires: 2035-02-13 | equity_swap_involved: false | shares_owned_after: 999,999.00 | transaction_form_type: 4 | Footnotes: F8
• Sold 25,279 shares of Stock Option (Right to Buy) at $0.72 per share (Derivative)
  Date: 2026-08-17 | Code: M | Expires: 2033-01-19 | equity_swap_involved: false | shares_owned_after: 110,931.00 | transaction_form_type: 4 | Footnotes: F5, F3
• Sold 29,737 shares of Stock Option (Right to Buy) at $0.72 per share (Derivative)
  Date: 2026-08-17 | Code: M | Expires: 2033-06-23 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F5, F3
• Sold 34,162 shares of Stock Option (Right to Buy) at $0.72 per share (Derivative)
  Date: 2026-08-18 | Code: M | Expires: 2033-06-23 | equity_swap_involved: false | shares_owned_after: 36,635.00 | transaction_form_type: 4 | Footnotes: F7
• Sold 34,987 shares of Stock Option (Right to Buy) at $0.72 per share (Derivative)
  Date: 2026-08-18 | Code: M | Expires: 2033-01-19 | equity_swap_involved: false | shares_owned_after: 75,944.00 | transaction_form_type: 4 | Footnotes: F5, F3
• Sold 13,268 shares of Stock Option (Right to Buy) at $0.72 per share (Derivative)
  Date: 2026-08-19 | Code: M | Expires: 2033-06-23 | equity_swap_involved: false | shares_owned_after: 23,367.00 | transaction_form_type: 4 | Footnotes: F7
• Sold 17,732 shares of Stock Option (Right to Buy) at $0.72 per share (Derivative)
  Date: 2026-08-19 | Code: M | Expires: 2034-02-14 | equity_swap_involved: false | shares_owned_after: 177,268.00 | transaction_form_type: 4 | Footnotes: F13
• Sold 30,918 shares of Stock Option (Right to Buy) at $0.72 per share (Derivative)
  Date: 2026-08-19 | Code: M | Expires: 2033-01-19 | equity_swap_involved: false | shares_owned_after: 45,026.00 | transaction_form_type: 4 | Footnotes: F5, F3

Footnotes:

• F1: This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F2: This transaction was executed in multiple trades at prices ranging from $1.46 to $1.5277, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F3: Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.
• F4: This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F5: The stock option is fully vested and exercisable.
• F6: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
• F7: 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
• F8: 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
• F9: This transaction was executed in multiple trades at prices ranging from $1.49 to $1.645, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F10: This transaction was executed in multiple trades at prices ranging from $1.48 to $1.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F11: This transaction was executed in multiple trades at prices ranging from $1.62 to $1.6995, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F12: This transaction was executed in multiple trades at prices ranging from $1.62 to $1.7006, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
• F13: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
• REMARKS: Title: Chief Operating and Development Officer